Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM).

Overseen By Andrew A Dwyer, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Boston College

Disqualifiers: Under 18, Not Hispanic, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

851 Participants Needed

Trial Summary

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Attitudes Toward Genomics and Precision Medicine (Spanish)?

The research indicates that healthcare professionals generally have positive attitudes toward precision medicine, which can help in making treatment decisions and providing prognostic information. However, there are concerns about costs, insurance, and knowledge gaps that need to be addressed for successful implementation. ^{1 2 3 4 5}

What safety data exists for pharmacogenomics and precision medicine treatments?

The research does not provide specific safety data for the treatment itself, but it discusses the importance of understanding drug-gene interactions and the potential for adverse drug reactions (ADRs) in pharmacogenomics. This suggests that while pharmacogenomics can help tailor treatments to individuals, there is a need to be cautious about possible ADRs. ^{6 7 8 9 10}

What is the purpose of this trial?

The investigators aim to evaluate English and Spanish versions of the "Attitudes toward genomics and precision medicine" instrument (AGPM). This study will help validating a Spanish version of the AGPM among people identifying as Hispanic, Latino, or Latina. Having a valid instrument is important for developing tailored interventions to decrease disparities in genomic healthcare for this population.

Research Team

Andrew A Dwyer, PhD

Principal Investigator

Boston College

Eligibility Criteria

This trial is for individuals identifying as Hispanic, Latino/a, or Latinx who have been diagnosed with Acute Lymphoblastic Leukemia. The study aims to include participants to validate a Spanish version of an attitudes survey on genomics and precision medicine.

Inclusion Criteria

I can give my consent electronically.

Identifying as Hispanic, Latino/a, or Latinx

Exclusion Criteria

I am under 18 years old.

Not identifying as Hispanic, Latino/a, or Latinx

I cannot give electronic consent.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Assessment

Participants complete the AGPM and other validated instruments to assess health literacy and numeracy

2 weeks

Follow-up

Participants are monitored for any additional data collection or feedback after the assessment

4 weeks

Treatment Details

Interventions

• Attitudes Toward Genomics and Precision Medicine (Spanish)

Trial Overview The trial is testing the reliability of two versions of a survey called 'Attitudes Toward Genomics and Precision Medicine' (AGPM), one in English and another in Spanish, among people from specific ethnic backgrounds.

Participant Groups

Group I: AGPM for Spanish Speakers Experimental Treatment 1 Intervention

Participants identifying as Hispanic, Latino, or Latina whose primary language is Spanish

Group II: AGPM for English Speakers Experimental Treatment 1 Intervention

Participants identifying as Hispanic, Latino, or Latina whose primary language is English

Who Is Running the Clinical Trial?

Boston College

Lead Sponsor

Trials

40

Recruited

49,300+

Findings from Research

Genetic testing carries potential patient safety risks at every stage, from ordering to analysis and follow-up, primarily due to a lack of physician knowledge and the rapid evolution of genetic technology.

To mitigate these risks, experts recommend enhancing physician education, providing access to genetic specialists, and improving communication through better test reports and electronic decision support systems.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient safety in genomic medicine: an exploratory study. Korngiebel, DM., Fullerton, SM., Burke, W.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach. [2023]

2. Germany pubmed.ncbi.nlm.nih.gov

Cancer patients' understandings of genetic variants of uncertain significance in clinical care. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

Precision Medicine: Familiarity, Perceived Health Drivers, and Genetic Testing Considerations Across Health Literacy Levels in a Diverse Sample. [2020]

4. United States pubmed.ncbi.nlm.nih.gov

Healthcare professionals' attitudes toward cancer precision medicine: A systematic review. [2023]

5. United States pubmed.ncbi.nlm.nih.gov

Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Patient safety in genomic medicine: an exploratory study. [2023]

7. Netherlands pubmed.ncbi.nlm.nih.gov

Public involvement in pharmacogenomics research: a national survey on patients' attitudes towards pharmacogenomics research and the willingness to donate DNA samples to a DNA bank in Japan. [2015]

8. United States pubmed.ncbi.nlm.nih.gov

Lay understandings of drug-gene interactions: The right medication, the right dose, at the right time, but what are the right words? [2022]

9. Switzerland pubmed.ncbi.nlm.nih.gov

Patients' Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. [2020]